BridgeBio Pharma, Inc. Common Stock (BBIO) Financial Statements
Historical financial data — 26 statements covering FY2019–FY2025
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs i...
BridgeBio Pharma, Inc. Common Stock's revenue increased 126.3% year over year, from $221.9M to $502.1M.
Net income decreased 35.3% over the same period, from $-535.8M to $-724.9M.
Over the 6-year period from FY2019 to FY2025, revenue grew by 1138% in total.
Total debt increased by 323.6% to $1.85B.
Operating cash flow grew 14.4% to $-445.9M.
BridgeBio Pharma, Inc. Common Stock maintains a negative net profit margin of -144.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $213.3M+5113.6% | $-108.7M | $212.1M | $-175.2M | $-144.8M | $794.4M | $435.4M | $-1.09B |
| Q3 FY2024 | $2.7M-98.7% | $-162.0M | $2.1M | $-191.8M | $-180.6M | $665.0M | $436.2M | $-1.23B |
| Q4 FY2024 | $5.9M+115.3% | $-265.1M | $3.8M | $-226.0M | $-195.3M | $919.3M | $437.3M | $-1.47B |
| Q1 FY2025 | $116.6M+1882.9% | $-167.4M | $114.0M | $-104.4M | $-199.2M | $881.6M | $0 | $-1.65B |
| Q2 FY2025 | $110.6M-5.2% | $-181.9M | $106.9M | $-134.3M | $-80.7M | $1.08B | $0 | $-1.79B |
| Q3 FY2025 | $120.7M+9.2% | $-182.7M | $114.1M | $-145.2M | $-109.6M | $998.3M | $1.85B | $-1.93B |
| Q4 FY2025 | $154.2M+27.7% | $-192.9M | $146.1M | $-139.6M | $-56.4M | $936.0M | $1.85B | $-2.09B |
| Q1 FY2026 | $194.5M+26.2% | $-164.0M | $184.6M | $-106.0M | $-197.3M | $1.37B | $1.93B | $-2.28B |
Balance Sheet Summary (Latest Period)
BridgeBio Pharma, Inc. Common Stock (BBIO) Financial Statements & Revenue History
BridgeBio Pharma, Inc. Common Stock (BBIO) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $67.22 with a market capitalization of $13. This page provides 26 historical financial statements for BridgeBio Pharma, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, BridgeBio Pharma, Inc. Common Stock reported revenue of $502 million, representing 126.3% year-over-year growth. The net profit margin of -144.4% indicates the company is currently unprofitable..
BBIO Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows BridgeBio Pharma, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BBIO is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BBIO's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently BridgeBio Pharma, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BBIO's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BBIO Financial Data
Investors use BridgeBio Pharma, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BBIO's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BBIO's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BBIO's financial health score, earnings, and pre-market pricing.
Financial data is sourced from BridgeBio Pharma, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BBIO trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.